白介素-10与炎症性肠病

Interleukin-10 and inflammatory bowel disease

炎症性肠病(inflammatory bowel disease,IBD)是一种慢性、复发性的肠道炎症疾病,其明确病因目前仍不清楚.肠道免疫功能异常导致过量炎症因子释放损伤肠道黏膜在IBD发病中起着关键作用,应用免疫抑制剂减少炎症因子的释放也被应用于IBD的治疗.近年来利用细胞因子调节机体免疫功能以治疗IBD的研究日渐增多,大量的实验及前期临床研究表明IL-10作为一种免疫调节因子,其对IBD良好的治疗效应预示着他将有可能为未来IBD治疗提供新的方法.然而,IL-10在临床应用尚存在瓶颈,如何更好地利用他使其发挥最大的生物学效应是未来的研究重点.目前已经出现了一些新型的方法,如利用基因修饰细菌、腺病毒编码IL-10以及联合Treg细胞等.本文将对IL-10在炎症性肠病的发病以及治疗方面的研究进展作一综述.

The etiology of inflammatory bowel disease （IBD） has not been fully elucidated. Evidence indicates that dysregulation of intestinal mucosal immunity plays a critical role in the pathogen- esis of IBD since it can cause overproduction of inflammatory cytokines and lead to uncontrolled intestinal inflammation. Cytokines play a pivotal role in modulating inflammation and may there-fore be a good target for IBD therapy. Interleukin-10 （IL-10） is a regulatory cytokine which inhibits both antigen presentation and subsequent pro-inflammatory cytokine release and has been proposed as a potent anti-inflammatory biological therapy for chronic IBD. Many IL-10-based strategies have been developed for treatment of IBD, including recombinant IL-10, genetically modified bacteria expressing IL-10, adenoviral vectors encoding IL-10, and combination therapy with IL-10 and Treg cells. The use of IL-10-based strategies will provide new insights into cell-and gene-based treatment for IBD.